MHM. Hummel

M. Hummel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


M. Hummel has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of donor-transmitted coronary atherosclerosis on outcome after heart transplantation

    by O. Grauhan, H. Chang, R. Meyer, N. Hiemann, W. Albert, H. Lehmkuhl, M. Dandel, M. Hummel, C. Knosalla, M. Pasic, et al.

    Background: Due to the shortage of donor hearts the criteria for organ acceptability have been considerably extended. Therefore, the probability of transmission of atherosclerotic lesions by means of transplantation has increased. The purpose of this study was to evaluate the impact of preexisting coronary atherosclerosis (CAS) on the outcome of transplantation. Material and Methods: Between 4/1986 and 12/2000 1253 patients underwent heart transplantation at our institution. In 1168 of these patients the coronary arteries were investigated by angiography (n=950) or autopsy (n=218) within 6 months after transplantation. Focal and noncircumferential atherosclerosis with 50% stenosis in proximal segments was regarded as native and transmitted CAS rather than transplant vasculopathy. Hazard function and Kaplan-Meier analysis were used. Results: In 82 patients CAS was diagnosed by angiography (n=49) or autopsy (n=33) (CAS group) and in 1086 patients no CAS was found (NCAS group). Early after HTX the instantaneous risk to die was threefold higher in the CAS group (0.17 vs. 0.05); however, beyond the first year the annual decrease in the CAS and NCAS groups was comparable (4.2%/year vs. 5.4%/year, p>0.05). Furthermore, incidence of graft vessel disease (GVD) and health-related quality of life (SF-36 questionnaire) were comparable (p>0.05). Only biopsy-proven micro-GVD, i.e. severe proliferative vascular wall thickening, was found more often in the CAS group after 5 years (83.8% vs. 74.9%, p=0.005) but this was without further clinical implications. Conclusions: Transmitted CAS impairs the short-term but not the long-term outcome after HTX. Nevertheless, coronary angiography of donor hearts should be performed liberally, i.e. in donors 40 years old.


  • Role of B Cells and Macrophages in Microvascular Disease After Heart Transplantation

    by N E Hiemann, R Meyer, M Hummel, E Wellnhofer, S Thomann, R Hetzer

    Background: The role of B cells and macrophages in microvascular disease after heart transplantation remains controversial. Methods: Out of a total of 809 endomyocardial biopsies without evidence of acute cellular rejection (n = 422, 72 females and 350 males, median age 46 years), 393 without evidence of the quilty phenomenon were investigated zero to ten years after heart transplantation. Vascular reaction (endothelial cell swelling and vessel wall thickening) was graded by H&E staining, and immunohistochemistry was performed for T cells (clone UCHL1), B cells (clone L26) and macrophages (clone KP1) and evaluated semi-quantitatively (light microscopy × 200). Results: Positive reaction for T cells and macrophages as well as evidence of endothelial cell swelling decreased with time after heart transplantation. Positive reactions for B cells were less frequent and increased slightly during the observation time, while vessel wall thickening dominated the last observation interval between the fourth and tenth years. Severity of vascular reaction was independent of immunohistochemical evidence of B cells or macrophages. Conclusions: While activation of the humoral and the non-specific immunological system is common after heart transplantation, microvascular alterations seem to develop independently of these findings. 1 Presented at the Annual Meeting of The German Society for Thoracic and Cardiovascular Surgery, Leipzig, February 22 - 26, 2003


  • Rad in combination with cyclosporine a in de novo heart transplant recipients: A two-year multicenter study to investigate the prevention of graft rejection and vasculopathy

    by H Lehmkuhl, R Hetzer, M Hummel, A Haverich, E Tuzcu, B Ulbricht, C Bara

    Objectives: This international, double-blind study investigates the safety and efficacy of RAD (everolimus) versus azathioprin (AZA) in de novo heart transplant recipients after 24-months. Material and Methods: Patients (n=634) were randomized into three treatment groups: RAD 1,5mg/day (n=209), RAD 3mg/day (n=211) or AZA 1–3mg/kg/day (n=214) in combination with cyclosporine A and steroids. Treatment failure defined as combined end-point of biopsy proven acute rejection (BPAR)=3A, BPAR with HDC, graft loss, death or lost to follow-up was investigated and graft-vasculopathy was evaluated by intravascular ultra-sound (IVUS). Results: Treatment failure was significantly lower with RAD 1,5mg (p=0,016) and 3mg (pConclusions: After 24-month treatment RAD has shown a superior efficacy compared with AZA particularly with respect to vasculopathy.

  • The prevalence and manifestation of Post Transplantation Lymphoproliferative Disorder (PTLD) in paediatric heart transplant recipients

    by B Schmitt, H Abdul-Khaliq, H Lehmkuhl, S Schubert, C Knosalla, M Hummel, M Dandel, R Hentze, Y Weng, Pe Lange, et al.

    Introduction: The reported prevalence of post-transplantation lymphoproliferative disorder (PTLD) in paediatric organ transplant recipients varied between 6% and 16%. Therefore, we evaluate the institutional incidence of PTLD in paediatric heart transplant recipients. Patients and Methods: The records of 110 paediatric patients who underwent heart transplantation at a young age between 1990 and 2002 were reviewed with respect to the occurrence of PTLD and EBV status. Immunosuppressive therapy consisted of triple-drug immunosuppresion with cyclosporin or FK506, steroids, and azathioprine or mycophenolate mofetil (MMF). Specific anti-viral prophylaxis was performed in all EBV-sero-negative children. Results: PTLD was diagnosed in 4 (3.6%) children with median age of 4 (range 1.3–13.3) years, after median post-transplant period of 3 years (range 4 months to 4.5 years). All of these patients received steroids, 3 set on cyclosporine and 1 on FK506. At the time of PTLD diagnosis 2 children received Azathioprine the other 2 received MMF. PTLD manifested predominantly as EBV-associated lymphoma: multiple abdominal nodules (n=2), femoral lymphoma (n=1), buccal lymphoma (n=1). The initial imaging findings of these episodes included bowel wall thickening, abdominal lymphadenopathy, and focal tumour masses. Only one patient suffered one recurrent episode of the lymphoma in orbital and buccal region. All patients are now in full remission without death after treatment including reduction of the immunosuppressive, anti-viral and chemo-therapy. Surgical procedures to remove tumours were necessary in all 4 patients. Conclusions: The manifestation of PTLD in young heart transplant recipients is predominately associated with EBV -infection. Close specific follow up and consequent anti-viral prophylaxis in EBV-sero-negative patients contributes to the relatively lower incidence of PTLD in our patients.

  • Noninvasive strategy for early prediction of allograft vasculopathy in transplanted hearts

    by M Dandel, F Knollmann, E Wellnhofer, H Lehmkuhl, M Hummel, O Grauhan, R Hetzer

    Transplant coronary arteriopathy (TxCA) surveillance by routine coronary angiographies often fails to detect stenoses prior to clinical events. After obtaining promising results for TxCA detection with pulsed-wave tissue Doppler [PW-TD] and electron-beam computed tomography [EBCT] separately, we assessed the diagnostic benefits of a combined use of both methods. Material and Methods: Throughout 18 months, 196 patients (post-transplant times >1 year) with normal left ventricle ejection fraction (LVEF) and without regional wall motion disturbances underwent EBCT (coronary calcification detection) and PW-TD (LV wall motion analysis) before coronary angiography. EBCT and PW-TD data were compared with angiographic findings. Results: The systolic peak velocity (Sm) and total calcification score (TCS) showed the highest predictive values for TxCA. We found significant differences (p=0.0001) between patients with and without stenoses of great epicardial coronaries for both TCS and Sm. Relevant stenoses (>50% occlusion) were absent in 99.2% of patients with both Sm >9cm/s and TCS values Conclusions: Serial PW-TD and annual EBCT are reliable for timing of cardiac catheterizations. They facilitate early diagnosis of coronary stenoses or their aggravation before the appearance of regional wall motion disturbances or alteration of the LVEF.

  • Everolimus in combination with cyclosporine A in de novo heart transplant recipients: A two-year multicenter study to investigate the prevention of graft rejection and vasculopathy

    by Hb Lehmkuhl, R Hetzer, M Hummel, A Haverich, Em Tuzcu, B Ulbricht, C Bara

    Objectives: An international, double-blind study to investigate safety and efficacy of everolimus (RAD) vs. azathioprin (AZA) in de novo heart transplant recipients after 24-month treatment. Material and Methods: 634 patients were randomized to one of three treatment groups: everolimus 1.5mg/day (n=209), everolimus 3mg/day (n=211) or AZA 1–3mg/kg/day (n=214) in combination with cyclosporine A microemulsion formulation, steroids and statins. The incidence of treatment failure defined as combined end-point of biopsy proven acute rejection (BPAR) ≥ 3A, BPAR with HDC, graft loss, death or lost to follow-up was investigated and graft-vasculopathy was evaluated by intravascular ultrasound (IVUS). Results: The incidence of treatment failure was significantly lower with everolimus 1,5mg (p=0.016) and 3mg (pConclusions: After 24-month treatment everolimus has shown a superior efficacy compared with AZA particularly concerning vasculopathy.

  • Herztransplantation in Deutschland 2002

    by M. Hummel, R. Hetzer

    Fünfunddreißig Jahre nach dem Beginn der ersten Transplantation ist die Herztransplantation ein etabliertes und chirurgisch weitgehend standardisiertes Verfahren zu Behandlung von Patienten mit terminaler Herzinsuffizienz geworden. Die verbesserte medikamentöse Behandlung der Herzinsuffizienz und die Entwicklung alternativer Behandlungsverfahren (z. B. Revaskularisation, Dreikammerherzschrittmacher, mechanische Kreislaufunterstützungssysteme) sowie die Entwicklung von Score-Systemen zur Prognosebeurteilung von Patienten mit unterschiedlichen Schweregraden der Herzinsuffizienz, erfordern eine Neubewertung der Indikationsstellung für die Herztransplantation. Die große Anzahl von transplantierten Patienten und die Ergebnisse von validen Studien mit neuen Immunsuppressiva lassen heute eine relativ zuverlässige Beurteilung der Risiken, Möglichkeiten und Grenzen der Transplantation zu. Diese Erfahrungen und Erkenntnisse sowie das 1999 verabschiedete deutsche Transplantationsgesetz haben zur Einführung eines neuen Allokationssystems geführt. Zudem wird durch die zentrale Dokumentation von Transplantationen eine vergleichende Beurteilung der Transplantationsergebnisse mit dem Ziel einer Qualitätssicherung möglich. After the first transplantation thirty-five years ago, heart transplantation has become an established and surgically widely standardized treatment modality for patients with end-stage heart failure. The improved medical therapy and alternative treatment options like revascularisation (CABAG), electrical resynchronization by a three-chamber pacemaker system or the implantation of mechanical assist device systems as well as the development of risk factor score systems to calculate the prognosis of patients with heart failure requires a new assessment of the indication for heart transplantation. The large number of heart transplanted patients and the results of randomized studies with new immunosuppressive drugs allow to calculate the risk, benefit and limitation of transplantation with relatively good reliability. These experiences and knowledge obtained and the German Transplantation Law, which passed the parliament in 1999, led to the establishment of a new heart allocation system. Additionally, by the central documentation of all transplantations in Germany, it becomes possible to compare the results of heart transplantations for better quality control.

  • Nicht-invasive Überwachung von Abstoßungsreaktionen nach Herztransplantation

    by J Müller, A Eubel, M Dandel, M Hummel, R Hetzer

    Hintergrund und Fragestellung: Die Endomyokardbiopsie ist der Goldstandard zur Abstoßungsüberwachung nach Herztransplantation. Bei Anwendung dieser invasiven Methode ist aufgrund von Abstoßungsreaktionen mit einer Mortalitätsrate von 5 - 6 % im ersten postoperativen Jahr zu rechnen. Das Ziel dieser retrospektiven Analyse war es, die diagnostische Zuverlässigkeit einer nichtinvasiven elektrophysiologischen Methode zur Abstoßungsüberwachung zu überprüfen. Patienten und Methodik: Dazu wurde täglich die QRS-Komplexamplitude des intramyokardialen Elektrogramms über einen Schrittmacher mit Telemetriefunktion in dem Zeitraum eines Jahres gemessen. Als Kriterium für den Verdacht einer Abstoßung wurde der Abfall der QRS-Komplexamplitude von mehr als 8 % gewertet. Von 734 Patienten wurden 558 in die Studie eingeschlossen. Eine Biopsie wurde nur dann vorgenommen, wenn die nichtinvasiven Methoden (QRS-Komplexamplitude plus Echokardiographie) diskrepante Ergebnisse zeigten. Ergebnisse: Keiner der Patienten starb an einer Abstoßungsreaktion, 273 wurden mindestens einmal und 285 nie biopsiert. Die Methode erreichte eine Sensitivität von 0,9777, eine Spezifität von 0,9634, einen negativen prädiktiven Wert von 0,9850 und einen positiven prädiktiven Wert von 0,9459. Folgerung: Die tägliche elektrophysiologische nichtinvasive Abstoßungsüberwachung scheint der invasiven Endomyokardbiopsie überlegen zu sein, da die durch Abstoßungsreaktionenen bedingte Mortalitätsrate bei gleichzeitiger geringerer Zahl an Endomyokardbiopsien deutlich reduziert werden konnte. Background and objective: Endomyocardial biopsy is the gold standard for monitoring rejection in cardiac recipients. The death rate due to rejection with this invasive method is 5-6 % in the first postoperative year. The aim of this retrospective data analysis from cardiac recipients was to prove the diagnostic reliability of a non-invasive electrophysiological method for rejection monitoring. Patients and methods: We daily analyzed the QRS-complex amplitude of the intramyocardial electrogram, which we received over a period from one year via a pacemaker with a telemetric capability. The diagnostic guideline for a suspected rejection was the reduction of the QRS-complex amplitude by more than 8 %. Out of 734 patients 558 were included in the study. Biopsy was only performed when the non-invasive rejection monitoring data (QRS-complex amplitude plus echocardiography) showed a discrepancy for rejection. Results: None of the patients died due to rejection, 273 at least once underwent a biopsy, and 285 never had a biopsy. The method reached a sensitivity of 0.9777, a specificity of 0.9634, a negative predictive value of 0.9850, and a positive predictive value of 0.9459. Conclusion: Daily electrophysiological non-invasive monitoring of rejection seems to be superior to endomyocardial biopsy. Death of patients due to rejection can be minimised. The number of necessary biopsies can be drastically reduced when compared to the usual number performed.